CAR-T Cell Safety Assessment I Pharmaron CRO

Pharmaron scientific poster on non-clinical safety evaluation of nanoparticle-delivered CAR-T cells. Call-to-action button says "Download Poster."

Poster Authors:

Yawen Bu; Xiaonan Liang; Jufeng Wang; Fan Yi

Pharmaron (Beijing) TSP Services Limited. Beijing, China.

Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment approach. However, traditional CAR-T engineering relies on viral vectors, which pose several challenges, including permanent CAR expression, high production costs, and safety concerns such as cytokine release syndrome and neurotoxicity. mRNA-lipid nanoparticle (mRNA-LNP) delivery is a cost-effective alternative, enabling temporary CAR expression and reduced toxicity.

In this study, we assessed mRNA-LNP-delivered CAR-T cells in a myeloma mouse model, investigating:

CAR-T cell efficacy
Biodistribution
Cytokine analysis
Immunophenotyping
Ophthalmological, clinical, and histological pathology

Download our CAR-T cell toxicology study.

Capabilities

Knowledge Center

Cell and Gene Therapy

CGT Safety Assessment

CGT in vivo Pharmacology Studies

Connect with a Scientific Expert

Complete the form below to access resource

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State(Required)

Message

Email(Required)

This field is hidden when viewing the form

Lead Source(Required)

By completing and submitting this form, you acknowledge that you have read and understood our Privacy Policy, and you consent to the collection and processing of your personal data by Pharmaron for the purpose of responding to your inquiry. You also agree to be contacted by Pharmaron regarding relevant services and updates. You may withdraw your consent at any time.